Impact of Baseline Central Retinal Thickness on Vision Among Patients With Diabetic Macular Edema: Post Hoc Analysis of the Phase 2/3 PHOTON Trial

David R Lally MD,[1] on behalf of the PHOTON study investigators

[1]New England Retina Consultants, Springfield, Massachusetts, USA

Presented at EURETINA, September 19–22, 2024

Disclosures

- Dr Lally has no conflicts of interest to disclose
- This trial was sponsored by Regeneron Pharmaceuticals, Inc. (Tarrytown, New York) and co-funded by Bayer AG (Leverkusen, Germany). The sponsors participated in the design and conduct of the trial, analysis of the data, and preparation of this presentation
- This trial includes research conducted on human patients. Institutional Review Board approval was obtained prior to study initiation
- Writing assistance by Disha Patel, PhD, Kaitlyn Scacalossi, PhD, and Stephanie Agbu, PhD, Regeneron Pharmaceuticals, Inc., is acknowledged

PHOTON Study Design

Multi-center, randomized, double-masked study in patients with DME[a]
Randomized 1 (2q8) : 2 (8q12) : 1 (8q16)
Note: 2-mg arm received 5 initial monthly injections versus 8-mg arms, which received only 3 initial monthly injections

2q8
Aflibercept 2 mg every 8 weeks after 5 initial monthly injections
n=167

8q12
Aflibercept 8 mg every 12 weeks after 3 initial monthly injections
n=328

8q16
Aflibercept 8 mg every 16 weeks after 3 initial monthly injections
n=163

Primary endpoint at Week 48
Mean change in BCVA (non-inferiority)

↓

End of study at Week 96
with optional 1-year extension through Week 156

[a]Treatment naive and previously treated.
2q8, 2 mg every 8 weeks; 8q12, 8 mg every 12 weeks; 8q16, 8 mg every 16 weeks; BCVA, best-corrected visual acuity; DME, diabetic macular edema.

Mean CRT Through Week 48



This analysis reports outcomes in eyes with varying baseline CRT treated with aflibercept 8 mg, informing treatment strategies

Observed values (censoring data post-ICE); FAS: 2q8 n=167; 8q12 n=328; 8q16 n=163 (at baseline).
CRT, central retinal thickness; Q, quartile.

Baseline Characteristics and Treatment Exposure to Week 48 by Baseline CRT Quartiles

	Q1: ≤360 µm (n=167)			Q2: ≥361 to ≤430 µm (n=163)			Q3: ≥431 to ≤528 µm (n=163)			Q4: >528 µm (n=164)		
	2q8 (n=47)	8q12 (n=85)	8q16 (n=35)	2q8 (n=39)	8q12 (n=78)	8q16 (n=46)	2q8 (n=36)	8q12 (n=92)	8q16 (n=35)	2q8 (n=45)	8q12 (n=72)	8q16 (n=47)
Age, years	63.3 (10.7)	61.7 (10.8)	62.9 (9.5)	64.1 (8.7)	63.9 (10.8)	62.5 (9.1)	63.9 (8.5)	62.0 (9.9)	60.4 (9.8)	61.2 (10.6)	60.8 (13.2)	61.4 (9.8)
Male, n (%)	28 (59.6)	56 (65.9)	21 (60.0)	17 (43.6)	47 (60.3)	26 (56.5)	18 (50.0)	51 (55.4)	22 (62.9)	29 (64.4)	55 (76.4)	30 (63.8)
Duration of diabetes, years	18.2 (11.6)	15.3 (9.6)	18.9 (12.5)	16.8 (9.8)	16.6 (11.1)	14.4 (10.1)	14.1 (9.31)	14.3 (9.4)	14.9 (9.0)	14.3 (8.8)	14.2 (9.7)	15.1 (10.7)
BCVA, ETDRS letters	64.8 (9.9)	66.6 (7.8)	68.4 (7.1)	63.1 (10.6)	66.1 (10.1)	64.0 (11.3)	61.3 (9.8)	64.0 (8.2)	62.4 (11.3)	56.7 (12.8)	57.4 (11.5)	53.1 (10.8)
CRT, µm	320.0 (22.1)	318.7 (26.4)	326.1 (23.9)	390.3 (18.6)	391.6 (21.3)	394.2 (19.4)	475.3 (32.5)	475.0 (29.1)	479.3 (28.5)	644.2 (128.2)	632.4 (114.8)	610.9 (77.5)
Treatment exposure to Week 48, mean injection	7.6	5.7	5.0	7.6	5.7	4.9	7.9	5.7	5.0	7.8	5.8	4.9

FAS. Unless otherwise specified, values shown represent mean (SD).
FAS, full analysis set; SD, standard deviation.

Mean BCVA and CRT Through Week 48 in Baseline CRT Q1 and Q2

Q1: ≤360 µm

Q2: ≥361 to ≤430 µm

BCVA





CRT





FAS, observed cases.

Mean BCVA and CRT Through Week 48 in Baseline CRT Q3 and Q4

BCVA

Q3: ≥431 to ≤528 µm



Q4: >528 µm



CRT





FAS, observed cases.

Mean BCVA and CRT Through Week 48 for Patients Without and With Prior DME Treatment in CRT Q4

Without Prior Treatment

With Prior Treatment

BCVA





CRT





FAS, observed cases.

Univariate Analysis: Impact of Baseline Characteristics on BCVA at Week 48 in CRT Q4

	2q8 (n=45)		8q12 (n=72)		8q16 (n=47)	
	Letters (95% CI)	*P*-value	Letters (95% CI)	*P*-value	Letters (95% CI)	*P*-value
Age (per 10-year increase)	–3.45 (–7.98, 1.09)	0.1322	–1.81 (–4.15, 0.53)	0.1266	–6.52 (–11.24, –1.80)	0.0081
HbA1c (per 1% increase)	–1.23 (–4.64, 2.18)	0.1685	–1.12 (–3.12, 0.88)	0.2671	–0.72 (–3.88, 2.43)	0.6455
Duration of diabetes (per 5-year increase)	–0.81 (–3.57, 1.94)	0.5541	–1.29 (–2.89, 0.31)	0.1109	–0.70 (–3.07, 1.68)	0.5554
BMI (per 5-kg/m^2 increase)	2.96 (–1.00, 6.92)	0.1381	–0.32 (–2.75, 2.12)	0.7960	1.55 (–2.84, 5.93)	0.4790
BCVA (per 5-letter increase)	4.06 (2.69, 5.42)	<0.0001	3.94 (2.99, 4.88)	<0.0001	6.36 (5.11, 7.60)	<0.0001
CRT (per 50-µm increase)	–2.34 (–4.08, –0.60)	0.0096	–0.43 (–1.77, 0.91)	0.5213	–0.64 (–3.99, 2.70)	0.6992
DRSS (≥47 to 90 vs ≤43)	–0.36 (–10.46, 9.74)	0.9433	1.22 (–5.42, 7.87)	0.7141	12.81 (1.99, 23.63)	0.0216
Prior DME treatment status (yes or no)	–7.67 (–16.54, 1.20)	0.0882	–3.17 (–9.53, 3.19)	0.3224	–12.60 (–22.34, –2.86)	0.0126
HbA1c (>8% vs ≤8%)	–5.20 (–14.58, 4.18)	0.2685	–4.68 (–11.19, 1.83)	0.1553	–7.77 (–18.95, 3.42)	0.1677

P-values were not adjusted for multiplicity.
BMI, body mass index; DRSS, Diabetic Retinopathy Severity Scale; HbA1c, hemoglobin A1c.

Multivariable Analysis: Impact of Baseline Characteristics on BCVA at Week 48 in CRT Q4



For every 5-letter increase in BCVA at baseline, there was a 4- to 6-letter increase in BCVA at Week 48

Univariate analysis included age, HbA1c, duration of diabetes, BMI, BCVA, CRT, DRSS ≤43 vs ≥47, prior DME treatment, and HbA1c >8% vs ≤8%. If more than 1 factor was significant ($P<0.05$) in univariate analysis, factors were then tested in multivariate analysis. *P*-values were not adjusted for multiplicity.

[a]Univariate analysis result. Only baseline BCVA was significantly associated with the BCVA outcome in the univariate analysis for 8q12, hence no multivariate analysis performed.

Mean CRT Through Week 48 in CRT Q4



Q4 baseline CRT: >528 µm.
FAS, observed cases.

Numerically Less Fluid Reaccumulation Was Observed With Aflibercept 8 mg Versus 2 mg Among Eyes in CRT Q4



Q4 baseline CRT: >528 µm.
FAS, observed cases.

Numerically Less Fluid Reaccumulation Was Observed With Aflibercept 8 mg Versus 2 mg Among Eyes in CRT Q4



Q4 baseline CRT: >528 µm.
FAS, observed cases.

Numerically Less Fluid Reaccumulation Was Observed With Aflibercept 8 mg Versus 2 mg Among Eyes in CRT Q4



CRT for 8q12 and 8q16 groups was similar 8 weeks after the third monthly dose

Q4 baseline CRT: >528 µm.
FAS, observed cases.

Numerically Less Fluid Reaccumulation Was Observed With Aflibercept 8 mg Versus 2 mg Among Eyes in CRT Q4



Q4 baseline CRT: >528 µm.
FAS, observed cases.

Numerically Less Fluid Reaccumulation Was Observed With Aflibercept 8 mg Versus 2 mg Among Eyes in CRT Q4



Q4 baseline CRT: >528 µm.
FAS, observed cases.

Numerically Less Fluid Reaccumulation Was Observed With Aflibercept 8 mg Versus 2 mg Among Eyes in CRT Q4



Q4 baseline CRT: >528 µm.
FAS, observed cases.

Numerically Less Fluid Reaccumulation Was Observed With Aflibercept 8 mg Versus 2 mg Among Eyes in CRT Q4



	8q12	8q16	2q8
ΔCRT 8 weeks after last monthly injection (µm)	+3.5	+5.7	+55.6

Q4 baseline CRT: >528 µm.
FAS, observed cases.

Majority of Aflibercept 8 mg Patients Maintained Randomized Dosing Intervals Through Week 48



Relatively more patients in CRT Q4 had intervals shortened through Week 48 versus in CRT Q1, Q2, and Q3

Q1: ≤360 µm; Q2: ≥361 to ≤430 µm; Q3: ≥431 to ≤528 µm; Q4: >528 µm.
FAS, patients who completed Week 48.
[a]Dosing intervals of patients who met study-specified DRM criteria for interval shortening (loss of >10 letters from Week 12 due to persistent or worsening DME and >50-µm increase in CRT from Week 12) at prespecified timepoints were shortened to either q12 or q8 weeks through Week 48.
DRM, dose regimen modification.

Conclusions

- Aflibercept 8 mg demonstrated meaningful visual and anatomic improvements in patients with DME at Week 48 across a wide range of baseline CRT values, with up to an average of 3 fewer injections compared with aflibercept 2 mg
- In eyes with baseline CRT >528 µm (Q4), fluid reaccumulation was numerically less 8 weeks after the third initial monthly dose with aflibercept 8 mg versus 8 weeks after the fifth initial monthly dose with aflibercept 2 mg, suggesting a more durable treatment effect